Compare SCTX & GSRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCTX | GSRF |
|---|---|---|
| Founded | N/A | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.1M | 298.8M |
| IPO Year | 2026 | 2025 |
| Metric | SCTX | GSRF |
|---|---|---|
| Price | $31.70 | $10.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 218.3K | 41.9K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $184.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.31 | $9.96 |
| 52 Week High | $39.60 | $10.22 |
| Indicator | SCTX | GSRF |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 74.21 |
| Support Level | $19.09 | $10.15 |
| Resistance Level | $39.60 | N/A |
| Average True Range (ATR) | 4.12 | 0.01 |
| MACD | 1.05 | 0.00 |
| Stochastic Oscillator | 66.75 | 100.00 |
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
GSR IV Acquisition Corp is a blank check company.